Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Anthony S. Stein, MD, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Max S. Topp, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Yan Li, Andre Schuh

Blood (2018) 132 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2018-99-115160

Published: 2018

Journal Articles

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Max S. Topp, Zachary F. Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, MD, Anthony S. Stein, MD, Janet L. Franklin, Ze Cong, PhD MS, Xinke Zhang, Andre Schuh

Blood (2018) 132 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2018-99-115123

Published: 2018

Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2018-99-112584

Published: 2018

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Alessandro Rambaldi, MD Prof, Françoise Rigal-Huguet, MD, Pavel Zak, Paul Cannell, MD, Kun Nie, PhD, Zachary F. Zimmerman, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 2552.

https://doi.org/10.1182/blood.V130.Suppl_1.2552.2552

Published: 2017

Journal Articles

Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study

Andrew Wei, MBBS, PhD FRACP, FRCPA, Josep-Maria Ribera, MD, Giovanni Martinelli, Richard A. Larson, MD, David Ritchie, MD PhD, Armin Ghobadi, MD, Yuqi Chen, Cedric E. Dos Santos, Zachary F. Zimmerman, MD PhD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2556.

https://doi.org/10.1182/blood.V130.Suppl_1.2556.2556

Published: 2017

Journal Articles

Memory Effector Cells but Not Effector Cells Derived from Naive T Cells Can Utilize a Non-Perforin and Non-FasL Pathway To Inhibit Allogeneic Progenitor Cell Function Ex-Vivo .

Zachary F. Zimmerman, BS, Monica V. Jones, BS, Stephen A. Stohlman, PhD, Robert B. Levy, PhD

Blood (2005) 106 (11): 3029.

https://doi.org/10.1182/blood.V106.11.3029.3029

Published: 2005

Journal Articles

Both Recipient T Naive and T Memory Cells Mediate Efficient Resistance Against Marrow Allografts in the Absence of Major Cytotoxic Effector Pathways.

Zachary F. Zimmerman, BS, Robert B. Levy, PhD.

Blood (2004) 104 (11): 2130.

https://doi.org/10.1182/blood.V104.11.2130.2130

Published: 2004

Journal Articles

Donor Antigen Presenting Cell CD80/86 Function Is Required for Eliciting T Cell Resistance Against Progenitor Cell Engraftment in an MHC Matched Allogeneic Non-Myeloablative Transplantation Model.

Zachary F. Zimmerman, BS, Robert B. Levy, PhD

Blood (2004) 104 (11): 2137.

https://doi.org/10.1182/blood.V104.11.2137.2137

Published: 2004

NARROW

Disease Burden Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study

Memory Effector Cells but Not Effector Cells Derived from Naive T Cells Can Utilize a Non-Perforin and Non-FasL Pathway To Inhibit Allogeneic Progenitor Cell Function Ex-Vivo .

Both Recipient T Naive and T Memory Cells Mediate Efficient Resistance Against Marrow Allografts in the Absence of Major Cytotoxic Effector Pathways.

Donor Antigen Presenting Cell CD80/86 Function Is Required for Eliciting T Cell Resistance Against Progenitor Cell Engraftment in an MHC Matched Allogeneic Non-Myeloablative Transplantation Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only